Also known as: Herzuma
Trastuzumab is marketed as HERCEPTIN and is a HER2/neu receptor antagonist used in HER2-overexpressing breast cancer and metastatic gastric/gastroesophageal junction adenocarcinoma. It is administered intravenously and requires companion diagnostic HER2 testing. U.S. initial approval was in 1998.
MIT engineers trained a language model on yeast codon usage to design genes that boost protein production, outperforming commercial tools for five of six proteins. The approach could lower drug development costs by improving yields of protein-based medicines.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
MIT chemical engineers used a large language model to optimize protein production in industrial yeast. The AI model improved yields for five of six tested proteins, including a cancer monoclonal antibody, potentially reducing drug development costs.
ALX Oncology has multiple 2026 catalysts for Evorpacept and ALX2004. Interim ASPEN-09 data are expected in Q3 2026, while an initial safety update from the phase 1 ALX2004 trial is expected in 1H 2026.
Over 20 pharmaceutical companies are developing therapies for HER2-positive gastric cancer, with multiple Phase III trials launched in March 2026 testing novel combination treatments for advanced disease.
Trastuzumab deruxtecan is moving into earlier treatment lines for HER2-positive metastatic breast cancer, demonstrating superior efficacy over standard regimens and prompting reconsideration of long-standing treatment sequences.
Recent developments in breast cancer treatment include new clinical trials for advanced disease, findings on CDK4/6 inhibitor sequencing, and discovery of genetic markers explaining drug resistance in HER2-positive breast cancer.
Exploratory analysis from a phase 1/2 trial shows CD47 expression levels predict response to evorpacept plus zanidatamab in heavily pretreated HER2-positive metastatic breast cancer patients, supporting biomarker-driven patient selection.
AIM ImmunoTech partners with Thermo Fisher to design Phase 3 trial for Ampligen in pancreatic cancer, while Innovent Biologics begins dosing patients in Phase 3 study of IBI354 for HER2-positive breast cancer.
New ASCO guideline emphasizes biomarker-driven treatment for advanced gastroesophageal cancer, recommending upfront testing for HER2, PD-L1, MSI/MMR, and CLDN18.2 to guide immunotherapy and targeted therapy selection.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07779538 |
Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT07766772 |
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07716046 |
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07694986 |
Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD |
RECRUITING | PHASE2 |
| NCT07683754 |
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd |
NOT_YET_RECRUITING | PHASE3 |
| NCT07679269 |
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07612215 |
Elacestrant in Advanced Triple Positive Breast Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT07578116 |
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07545044 |
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07528898 |
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. |
NOT_YET_RECRUITING | PHASE2 |
